Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Vivakor Announces 1-for-20 Reverse Stock Split

Vivakor Announces 1-for-20 Reverse Stock Split

Vivakor, Inc., a provider of integrated energy transportation and remediation services, announced a 1-for-20 reverse stock split effective July 17, 2026. The move aims to increase the per-share trading price and support the company's continued listing on the Nasdaq Capital Market. Shareholders approved a range of reverse splits at the 2026 annual m…

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

DBV Technologies, a late-stage biopharmaceutical company focused on food allergy treatments using its VIASKIN® patch technology, will report its second quarter 2026 financial results and provide a business update on July 16, 2026. The company will host a conference call and webcast for investors to discuss the results and ongoing clinical trial pro…

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical announced the publication of two-year follow-up data from its VNS-REHAB pivotal trial in the journal Neurology, demonstrating sustained and clinically meaningful improvements in upper-limb motor function, daily living activities, and quality of life in chronic ischemic stroke survivors using the Vivistim Paired VNS Therapy. The data s…

Disciplined Growth Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing July 17, 2026

Disciplined Growth Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing July 17, 2026

Disciplined Growth Acquisition Corporation announced that starting July 17, 2026, investors can separately trade its Class A ordinary shares and rights, which were part of the units sold in its IPO. The shares and rights will trade under the symbols DGAC and DGACR respectively, while units not separated will continue trading as DGACU. The company i…

H2O America to Report Second Quarter 2026 Financial Results on July 27

H2O America to Report Second Quarter 2026 Financial Results on July 27

H2O America, a national investor-owned water and wastewater utilities network, will report its Q2 2026 financial results post-market on July 27, followed by a conference call on July 28 to discuss the results and recent developments. The company emphasizes its commitment to delivering clean water to over 1.6 million people across the U.S. through i…

Elite Express Holding Inc. Reports Second Quarter 2026 Results

Elite Express Holding Inc. Reports Second Quarter 2026 Results

Elite Express Holding Inc. reported a 15.3% revenue increase to $726,829 in Q2 2026, driven by higher fixed revenues and an ISP agreement with FedEx. Gross profit improved significantly due to revenue growth outpacing costs. However, substantial increases in general and administrative expenses and a $2.15 million R&D investment caused net losses to…

Paylocity announces Q4 FY26 earnings conference call

Paylocity announces Q4 FY26 earnings conference call

Paylocity Holding Corporation announced its upcoming conference call to discuss fourth quarter and fiscal 2026 results, scheduled for August 4, 2026. The company provides cloud-based HR, Finance, and IT software solutions, promoting an integrated platform with AI-driven features to enhance workplace operations.

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC Pharmaceuticals announced the initiation of the global Phase 3 Himalayas-1 trial evaluating rinzimetostat in combination with Bayer's darolutamide (NUBEQA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone. The trial will enroll approximately 600 patients across 25 countries to assess …